News

The randomized, double blind, multicenter, parallel-group Phase III trial is designed to evaluate the safety and efficacy of DCVAC/PCa as an add-on therapy to 1st line standard of

The exclusive license grants GCA Therapeutics the right to clinically develop and commercialize Leptin Products in China, exclusive of Hong Kong, and Taiwan. The company said that a

The company said that EscharEx is based on its patented proteolytic enzyme technology. About 72 patients are expected to be enrolled in the prospective, randomized, controlled, multicenter Phase

The loan will support the development of LP2, the first peptide-based drug , for treatment of Idiopathic Pulmonary Fibrosis. LP2 is an innovative lanthipeptide used to activate the

The deal, which is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development, is focused on identifying, validating, and screening novel

BioMAP Combo ELECT enables the in vitro testing of drug combinations in the context of human biology for potential safety risks and improved therapeutic effects, thus supporting the

In the suit, Acura alleges that a generic of Acura’s AVERSION oxycodone product, previously marketed by Pfizer Inc. under its brand name OXECTA, for which Sandoz is seeking

Developed by PAREXEL Informatics, it is a key component of the Perceptive MyTrials eClinical platform, an integrated suite of applications for managing clinical trials. On-site monitoring is a

AntiOp founder Dr. Daniel Wermeling said that this partnership leverages the company’s combined resources and strengths. "AntiOp has the technical expertise and R&D experience to deliver a specifically-designed